Category: Inclisiran

by biotechbrothers January 18, 2020 0

The Flop of the Decade: A PCSK9 Inhibitor with a Price Tag of $14,100

The cardiovascular disease is a lucrative market for many pharmaceutical and biotechnology companies to break in. It is estimated thatContinue Reading

by biotechbrothers November 26, 2019 1

acquisitions Biology Biopharma Biopharmaceuticals biotech Biotech Billionaire Biotech Hub Breaking In Biotech Buyout Inclisiran low-density lipoprotein (LDL) Medicine Co. Novartis ow-density lipoprotein Pcsk9 PCSK9 Inhibitor Pharma Science siRNA The Medicines Company

Novartis Acquires The Medicines Company for $9.7 Billion

A Global Switzerland Pharmaceutical, Novartis, has agreed to acquire Medicines Company (NASDAQ: MDCO) for a staggering $9.7 Billion. The MedicinesContinue Reading